Paul N. Mudd

1.8k total citations
39 papers, 640 citations indexed

About

Paul N. Mudd is a scholar working on Urology, Rheumatology and Epidemiology. According to data from OpenAlex, Paul N. Mudd has authored 39 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Urology, 18 papers in Rheumatology and 17 papers in Epidemiology. Recurrent topics in Paul N. Mudd's work include Urinary Bladder and Prostate Research (19 papers), Pelvic floor disorders treatments (13 papers) and Urinary Tract Infections Management (11 papers). Paul N. Mudd is often cited by papers focused on Urinary Bladder and Prostate Research (19 papers), Pelvic floor disorders treatments (13 papers) and Urinary Tract Infections Management (11 papers). Paul N. Mudd collaborates with scholars based in United States, United Kingdom and Netherlands. Paul N. Mudd's co-authors include Denise Shortino, Rachael Jankowich, Jeffrey Frankel, David Staskin, Cynthia J. Girman, Franklin K. Johnson, Roger R. Dmochowski, Kristy Iglay, Julie J. Paik and Ekene Enemchukwu and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of the Rheumatic Diseases.

In The Last Decade

Paul N. Mudd

39 papers receiving 615 citations

Peers

Countries citing papers authored by Paul N. Mudd

Since Specialization

Citations

This map shows the geographic impact of Paul N. Mudd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul N. Mudd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul N. Mudd more than expected).

Fields of papers citing papers by Paul N. Mudd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul N. Mudd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul N. Mudd. The network helps show where Paul N. Mudd may publish in the future.

Co-authorship network of co-authors of Paul N. Mudd

This figure shows the co-authorship network connecting the top 25 collaborators of Paul N. Mudd. A scholar is included among the top collaborators of Paul N. Mudd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul N. Mudd. Paul N. Mudd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient reported physical function, mental health, and treatment patterns in dermatomyositis: survey results from a cross-sectional study of adult dermatomyositis patients 2025 ·BMC Rheumatology ·Lisa Christopher‐Stine, Julie J. Paik, (unknown), Paul N. Mudd	1
2	Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis 2024 ·Clinical and Experimental Rheumatology ·Julie J. Paik, Jiří Vencovský, Christina Charles‐Schoeman, Grace C. Wright, Ruth Ann Vleugels, (unknown), Paul N. Mudd, Rohit Aggarwal	5
3	AB1717-PARE DERMATOMYOSITIS BURDEN OF DISEASE MANIFESTATIONS AND QOL IMPACT: PATIENT-REPORTED SURVEY RESULTS 2023 ·Annals of the Rheumatic Diseases ·(unknown), Jeremy Feldman, Timothy L. Smith, Paul N. Mudd, Julie J. Paik	1
4	Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial 2022 ·International Journal of Clinical Practice ·David Staskin, Jeffrey Frankel, (unknown), Michael Kennelly, Diane K. Newman, Matt T. Rosenberg, Denise Shortino, Rachael Jankowich, Paul N. Mudd	10
5	Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors 2022 ·Current Therapeutic Research ·Benjamin M. Brucker, (unknown), Paul N. Mudd, (unknown)	22
6	Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison 2021 ·Advances in Therapy ·Michael Kennelly, Thomas Rhodes, Cynthia J. Girman, Elizabeth Thomas, Denise Shortino, Paul N. Mudd	19
7	Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR 2021 ·Advances in Therapy ·Jeffrey Frankel, David Staskin, (unknown), Michael Kennelly, Diane K. Newman, Matt T. Rosenberg, Rachael Jankowich, Denise Shortino, Paul N. Mudd, Cynthia J. Girman	8
8	Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study 2021 ·Drugs & Aging ·(unknown), David Staskin, Jeffrey Frankel, Denise Shortino, Rachael Jankowich, Paul N. Mudd	17
9	Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial 2021 ·Blood Pressure Monitoring ·Michael A. Weber, Cornelia Haag‐Molkenteller, (unknown), (unknown), Paul N. Mudd, William B. White	5
10	MP63-15 VIBEGRON FOR THE TREATMENT OF PATIENTS WITH DRY OVERACTIVE BLADDER: A SUBGROUP ANALYSIS FROM THE EMPOWUR TRIAL 2021 ·The Journal of Urology ·David Staskin, Jeffrey Frankel, (unknown), Michael Kennelly, Diane K. Newman, Matt T. Rosenberg, Denise Shortino, Rachael Jankowich, Paul N. Mudd	1
11	Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis 2020 ·Drugs in Context ·Michael Kennelly, Ronald C. Wielage, Denise Shortino, Elizabeth Thomas, Paul N. Mudd	10
12	PUK5 OVERACTIVE BLADDER IN THE UNITED STATES LONG-TERM CARE SETTING IS ASSOCIATED WITH SIGNIFICANT BURDEN AND INCREASED HEALTHCARE RESOURCE UTILIZATION AND COSTS: A RETROSPECTIVE DATABASE STUDY 2020 ·Value in Health ·Jason Yeaw, Drishti Shah, (unknown), Paul N. Mudd	2
13	Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study 2020 ·International Journal of Clinical Practice ·Jeffrey Frankel, (unknown), David Staskin, Denise Shortino, Rachael Jankowich, Paul N. Mudd	16
14	PD21-01 ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB) 2020 ·The Journal of Urology ·(unknown), Jeffrey Frankel, (unknown), Denise Shortino, Rachael Jankowich, Paul N. Mudd	2
15	Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial 2018 ·European Urology ·H. David Mitcheson, Suvajit Samanta, (unknown), Cathy Anne Pinto, (unknown), Stuart Green, Nathan Bennett, Paul N. Mudd, Tara L. Frenkl	46
16	Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects 2013 ·PubMed ·(unknown), Naoki Takahashi, (unknown), Paul N. Mudd, Toshiyasu Hirama	6
17	Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia 2013 ·Cancer Chemotherapy and Pharmacology ·(unknown), Paul N. Mudd, Danièle Ouellet, Brendan M. Johnson, Daphne Williams, Ekaterina Gibiansky	16
18	Probabilistic Risk Analysis: Improving Early Drug Development Decision Making 2010 ·Clinical Pharmacology & Therapeutics ·Paul N. Mudd, Huybert Groenendaal, Mark Bush, Virginia D. Schmith	7
19	Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys 2004 ·Carcinogenesis ·Debie J. Hoivik, Charles W. Qualls, Rosanna C. Mirabile, Neal F. Cariello, (unknown), Heidi M. Colton, Steven P. Anderson, Michael J. Santostefano, (unknown), (unknown), Alan R. Brown, Zhiyang Zhao, Paul N. Mudd, (unknown), H. Roger Brown, Richard T. Miller	56
20	Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients 1998 ·Anti-Cancer Drugs ·Mark A. Socinski, Paul N. Mudd, (unknown), (unknown), (unknown), Stephen A. Bernard, Stephen P. Letrent, Pablo Gonzalez, Kim L. R. Brouwer	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact